PTC Therapeutics Inc. (PTCT) Wells Fargo 20th Annual Healthcare Conference 2025 Transcript

Tiago Fauth
Equity Analyst

All right. Thanks, everyone, for joining us. I’m Tiago Fauth. I’m a biotech analyst here at Wells Fargo. We have PTC Therapeutics joining us at our health care conference this year. Thank you so much for spending the time.

We have Matt and Pierre for a fireside chat. I usually like to give you guys some time just for quick intros overall setup. Again, PTC has been changed substantially over the last 18 months, 2 years. So yes, if you can give like the brief intro and then again, a detailed discussion on Sephience and some aspects of the business.

Matthew Klein
CEO & Director

Yes, absolutely. Thanks, Tiago. It’s great to be here. And as you said, we’re really at a point in time today where a lot of the work we’ve put in over the past 1.5 years to 2 years to shed a lot of legacy challenges and position ourselves for future success has come to fruition. We recently had our global approvals of Sephience begin, including both the U.S. and Europe. And as we talked about, we see that as a significant commercial opportunity for the company that can take us to cash flow breakeven and beyond in the near future.

We closed the second quarter with over $1.9 billion in cash. So we come to this point in time where we can move towards cash flow breakeven with sufficient capital in the bank, not only to get us there, but execute on all of our commercial and R&D priorities as well